IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) insider Bhavik Patel sold 1,855 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the sale, the insider directly owned 1,348 shares in the company, valued at approximately $317,143.96. This represents a 57.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
IQVIA Trading Down 1.5%
Shares of IQVIA stock opened at $232.41 on Friday. The company has a 50-day moving average of $199.81 and a two-hundred day moving average of $186.59. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $38.26 billion, a PE ratio of 28.84, a price-to-earnings-growth ratio of 2.00 and a beta of 1.18.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company earned $2.81 EPS. The company’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.
Hedge Funds Weigh In On IQVIA
Institutional investors and hedge funds have recently modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new stake in IQVIA in the 4th quarter worth approximately $25,000. Financial Freedom LLC acquired a new stake in shares of IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors purchased a new stake in shares of IQVIA in the first quarter valued at $25,000. International Assets Investment Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in IQVIA in the fourth quarter valued at $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Analyst Ratings Changes
Several equities research analysts recently commented on the stock. Robert W. Baird boosted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Mizuho increased their price target on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Morgan Stanley reissued an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Finally, Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.88.
Check Out Our Latest Stock Report on IQV
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Recommended Stories
- Five stocks we like better than IQVIA
- Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling
- 4 Oil and Gas ETF Plays as Prices Stay Sky-High
- What Tesla Stands to Lose If It Walks Away From China
- Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
